BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28374895)

  • 1. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
    Guo R; Yang J; Liu X; Wu J; Chen Y
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
    Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
    J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
    Al-Awadhi A; Adekile A; Marouf R
    J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
    Edvardsen MS; Hansen ES; Ueland T; Aukrust P; Brækkan SK; Morelli VM; Hansen JB
    J Thromb Haemost; 2023 May; 21(5):1227-1237. PubMed ID: 36736832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
    Mannucci PM; Capoferri C; Canciani MT
    Br J Haematol; 2004 Jul; 126(2):213-8. PubMed ID: 15238142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease.
    Hunt R; Hoffman CM; Emani S; Trenor CC; Emani SM; Faraoni D; Kimchi-Sarfaty C; Ibla JC
    J Thromb Haemost; 2017 Dec; 15(12):2306-2316. PubMed ID: 28981194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
    Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
    Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.
    Kremer Hovinga JA; Zeerleder S; Kessler P; Romani de Wit T; van Mourik JA; Hack CE; ten Cate H; Reitsma PH; Wuillemin WA; Lämmle B
    J Thromb Haemost; 2007 Nov; 5(11):2284-90. PubMed ID: 17764538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients.
    Martini F; Ferroni P; Guadagni F; Basili S; Spila A; D'Alessandro R; Mineo D; Laudisi A; Portarena I; Mariotti S; Ambrogi V; Mineo TC; Roselli M
    Anticancer Res; 2005; 25(1B):403-7. PubMed ID: 15816602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
    Al-Awadhi A; Adekile A; Marouf R
    Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty.
    Bander J; Elmariah S; Aledort LM; Dlott J; Stelzer P; Halperin JL; Kini AS; Sharma SK
    Thromb Haemost; 2012 Jul; 108(1):86-93. PubMed ID: 22627470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.
    Habe K; Wada H; Higashiyama A; Akeda T; Tsuda K; Mori R; Kakeda M; Matsumoto T; Ohishi K; Yamanaka K; Katayama N; Mizutani H
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):920-927. PubMed ID: 29130325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
    Favaloro EJ; Henry BM; Lippi G
    Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.
    Djamiatun K; van der Ven AJ; de Groot PG; Faradz SM; Hapsari D; Dolmans WM; Sebastian S; Fijnheer R; de Mast Q
    PLoS Negl Trop Dis; 2012; 6(5):e1628. PubMed ID: 22563509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
    Karakaya B; Tombak A; Serin MS; Tiftik N
    Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.
    Soares RP; Bydlowski SP; Nascimento NM; Thomaz AM; Bastos EN; Lopes AA
    Braz J Med Biol Res; 2013 Apr; 46(4):375-81. PubMed ID: 23558858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.
    Castelli R; Bergamaschini L; Teatini T; Cilumbriello L; Schiavon R; Gallipoli P; Deliliers GL
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e461-e467. PubMed ID: 32507387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.